Older people with chronic schizophrenia.
ABSTRACT Older people with chronic schizophrenia are a numerically small but important group with complex clinical and service needs. Along with a reduction in positive schizophrenic symptoms with increasing age, a majority suffer from negative symptoms, cognitive deficits, depression, side effects due to long-term use of antipsychotics and co-morbid medical problems. They may have social disabilities making them vulnerable to poverty, isolation and poor quality of life. Evidence suggests that judicious use of antipsychotics combined with psychotherapy and psychosocial interventions are effective. There are shortcomings in the standard of both hospital and community care, and the cost implications of providing adequate services are high.
SourceAvailable from: R. Tourtauchaux[Show abstract] [Hide abstract]
ABSTRACT: After 65-years-old, the prevalence of schizophrenia is included into 0.1% to 0.5%. Most older people with schizophrenia will have developed the illness before the age of 45 and 85% of them live in the community. Although about one out of seven persons with schizophrenia is aged 65 and older, and the number of elderly with schizophrenia will increase in the next years, only 1% of literature on schizophrenia is dedicated to questions related to aging. Schizophrenia, a real mental disability, has an important repercussion on global functioning and particularly on quality of life (QOL). QOL of aging persons with schizophrenia is determined by many factors and doesn’t only limit to symptoms presented by the patient.Annales Médico-psychologiques revue psychiatrique 06/2009; 167(5):392-396. DOI:10.1016/j.amp.2009.04.013 · 0.15 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: This paper reports on a new technology of simultaneous measurements of micro-fluorescent-particle position in 3D and of temperature field with high time-resolution. The technology to measure both velocity and temperature field is based on the simultaneity of micro digital holographic particle tracking velocimetry (micro-DHPTV) and laser-induced fluorescence (LIF).Microelectronic Engineering 08/2011; 88(8):1875-1877. DOI:10.1016/j.mee.2010.12.033 · 1.34 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: Disturbances of lipid and glucose metabolism have been repeatedly reported in schizophrenia. A functional L162V polymorphism in peroxisome proliferator-activated receptor alpha (PPARα) gene has been extensively investigated in etiology of abnormal lipid and glucose metabolism, yet not in schizophrenia. We determined whether the schizophrenia risk was associated with L162V polymorphism and we examined the impact of L162V variant on age of onset, and data of psychopathology scores. We also hypothesized that plasma glucose and lipid concentrations in patients may be influenced by L162V polymorphism. Genotype and allele frequencies between 203 patients and 191 controls did not differ significantly. Females heterozygous for the PPARα genotype (L162V) manifested significantly lower negative symptom scores, tended toward an earlier onset, and had significantly greater triglyceride levels. The PPARα-L162V polymorphism is not associated with schizophrenia risk in Croatian population, but it impacts clinical expression of the illness and plasma lipid concentrations in female patients.Prostaglandins Leukotrienes and Essential Fatty Acids 11/2014; DOI:10.1016/j.plefa.2014.07.003 · 1.98 Impact Factor